|
|
Aging Research 2024
非小细胞肺癌老年患者免疫治疗后相继出现免疫性肺炎与免疫性肝炎1例
|
Abstract:
目的：探讨卡瑞利珠单抗导致非小细胞肺癌患者相继出现免疫性肺炎与免疫性肝炎的防治原则及潜在的机制，保证患者安全用药。方法：回顾1例非小细胞肺癌患者接受卡瑞利珠单抗治疗的病程变化，结合卡瑞利珠单抗相关的临床研究、相关不良反应的诊疗规范，对本案例进行分析。结果：卡瑞利珠单抗导致患者出现免疫性肺炎与免疫性肝炎，期间未予停药，免疫性肺炎给予激素治疗、免疫性肝炎给予对症处理后好转，患者预后良好。结论：使用卡瑞利珠单抗抗肿瘤免疫治疗过程中，需要参考权威指南、结合患者实际情况，持续监测患者的免疫相关不良反应，保证患者用药的安全性及有效性。
Objective: To explore the prevention and treatment principle and potential mechanism of immune pneumonia and immune hepatitis in patients with non-small cell lung cancer caused by camrelizumab. Methods: The course of a patient with non-small cell lung cancer who was treated with camrelizumab was reviewed, and the case was analyzed in combination with the clinical studies related to camrelizumab and the standard of diagnosis and treatment of related adverse reactions. Results: After treatment with camrelizumab, the patient developed immune pneumonia and immune hepatitis, during that period, the drug was not stopped. Immune pneumonia was treated with hormone and immune hepatitis was treated with symptomatic treatment, and the prognosis was good. Conclusion: In the process of tumor immunotherapy with camrelizumab, it is necessary to refer to authoritative guidelines, combined with the actual situation of patients, and continuously monitor the immune-related adverse reactions of patients to ensure the safety and effectiveness of drug use.
| [1] | Markham, A. and Keam, S.J. (2019) Camrelizumab: First Global Approval. Drugs, 79, 1355-1361.
https://doi.org/10.1007/s40265-019-01167-0 |
| [2] | Mo, H., Huang, J., Xu, J., et al. (2018) Safety, Anti-Tumour Activity, and Pharmacokinetics of Fixed-Dose SHR-1210, an Anti-PD-1 Antibody in Advanced Solid Tumours: A Dose-Escalation, Phase 1 Study. British Journal of Cancer, 119, 538-545. https://doi.org/10.1038/s41416-018-0100-3 |
| [3] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南-2023 [M]. 北京: 人民卫生出版社, 2023. |
| [4] | 余敏, 李歆. 528例卡瑞利珠单抗治疗的免疫相关不良反应及风险因素分析[J]. 中国药物警戒, 2023, 20(10): 1134-1140. |
| [5] | Tong, Z.Q., Wu, D.Y., Liu, D., et al. (2021) Incidence Risk of PD-1/PD-L1-Related Pneumonia and Diarrhea in Non-Small Cell Lung Cancer (NSCLC) Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. European Journal of Clinical Pharmacology, 77, 1079-1088. https://doi.org/10.1007/s00228-020-03083-9 |
| [6] | Huang, J., Xu, J., Chen, Y., et al. (2020) Camrelizumab versus Investigator’s Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 21, 832-842. https://doi.org/10.1016/S1470-2045(20)30110-8 |
| [7] | Song, Y., Wu, J., Chen, X., et al. (2019) A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clinical Cancer Research, 25, 7363-7369.
https://doi.org/10.1158/1078-0432.CCR-19-1680 |
| [8] | Suresh, K., Voong, K.R., Shankar, B., et al. (2018) Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology, 13, 1930-1939.
https://doi.org/10.1016/j.jtho.2018.08.2035 |
| [9] | Frost, N., Unger, K., Blum, T.G., et al. (2023) Management, Risk Factors and Prognostic Impact of Checkpoint-Inhibitor Pneumonitis (CIP) in Lung Cancer—A Multicenter Observational Analysis. Lung Cancer, 179, Article ID: 107184.
https://doi.org/10.1016/j.lungcan.2023.107184 |
| [10] | Ahn, M.J., Cho, B.C., Ou, X., et al. (2022) Osimertinib plus Durvalumab in Patients with EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. Journal of Thoracic Oncology, 17, 718-723.
https://doi.org/10.1016/j.jtho.2022.01.012 |
| [11] | Li, Y., Jia, X., Zhang, Y., et al. (2023) Risk Factors and Immunomodulators Use in Steroid-Refractory Checkpoint Inhibitor Pneumonitis. The Journal for ImmunoTherapy of Cancer, 11, e006982.
https://doi.org/10.1136/jitc-2023-006982 |
| [12] | Zhang, L., Zhang, M., Xu, J., et al. (2020) The Role of the Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Pathway, Regulatory T Cells and T Helper 17 Cells in Tumor Immunity: A Narrative Review. Annals of Translational Medicine, 8, Article No. 1526. https://doi.org/10.21037/atm-20-6719 |
| [13] | Yin, J., Wu, Y., Yang, X., et al. (2022) Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. Frontiers in Immunology, 13, Article 830631.
https://doi.org/10.3389/fimmu.2022.830631 |
| [14] | Wussler, D., Kozhuharov, N., Tavares, O.M., et al. (2019) Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clinical Chemistry, 65, 1532-1542. https://doi.org/10.1373/clinchem.2019.306787 |
| [15] | Zhang, Y.B., Liu, S.J., Hu, Z.D., et al. (2020) Increased Th17 Activation and Gut Microbiota Diversity Are Associated with Pembrolizumab-Triggered Tuberculosis. Cancer Immunology, Immunotherapy, 69, 2665-2671.
https://doi.org/10.1007/s00262-020-02687-5 |
| [16] | Qin, S., Ren, Z., Meng, Z., et al. (2020) Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 571-580.
https://doi.org/10.1016/S1470-2045(20)30011-5 |
| [17] | Younes, A., Santoro, A., Shipp, M., et al. (2016) Nivolumab for Classical Hodgkin’s Lymphoma after Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial. The Lancet Oncology, 17, 1283-1294. https://doi.org/10.1016/S1470-2045(16)30167-X |
| [18] | Kundumadam, S., Mohamad, B., Muthusamy, A., et al. (2020) Pembrolizumab-Induced Immune-Mediated Hepatitis and Concurrent Hepatitis B Reactivation in a Patient with Non-Small Cell Lung Cancer. Cureus, 12, e11522.
https://doi.org/10.7759/cureus.11522 |
